Halozyme Therapeutics' Q2 revenue up 41%, beats estimates

Halozyme Therapeutics

05/08/2025 21:14

Overview

Halozyme Q2 2025 rev grows 41% yr/yr, beating analyst expectations, per LSEG data

Adjusted EPS for Q2 2025 beats consensus, rising 69% yr/yr, per LSEG data

Co raises 2025 guidance, announces third $250 mln share repurchase tranche

Outlook

Halozyme raises 2025 revenue guidance to $1,275 mln-$1,355 mln

Company expects 2025 royalty revenue of $825 mln-$860 mln

Halozyme forecasts 2025 adjusted EBITDA of $865 mln-$915 mln

Company sees 2025 non-GAAP EPS at $6.00-$6.40

Result Drivers

ROYALTY REVENUE - 65% increase in royalty revenue driven by blockbuster therapies DARZALEX SC, Phesgo, and VYVGART Hytrulo

REGULATORY APPROVALS - Multiple approvals, including RYBREVANT SC in Europe and VYVGART Hytrulo for CIDP, expected to boost future growth

ENHANZE TECHNOLOGY - High-margin royalty streams and global demand for ENHANZE technology cited as key growth drivers

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$326 mln
$285.90 mln (7 Analysts)
Q2 Adjusted EPS
Beat
$1.54
$1.27 (5 Analysts)
Q2 EPS
$1.33
Q2 Net Income
$165 mln
Q2 Operating Income
$202.40 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Halozyme Therapeutics Inc is $68.50, about 12.4% above its August 4 closing price of $59.99

The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release: ID:nPn7gmLcSa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)